Literature DB >> 20405223

Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.

Pascal Gervaz1, Laura Rubbia-Brandt, Axel Andres, Pietro Majno, Arnaud Roth, Philippe Morel, Gilles Mentha.   

Abstract

BACKGROUND: We report the histopathological results of a novel "inversed" strategy designed to manage patients with colorectal cancer (CRC) who have synchronous liver metastases by using chemotherapy first, liver surgery second, and resection of the primary tumor as a final step. This study was designed to compare the response to chemotherapy in liver metastases, primary tumors, and locoregional lymph nodes.
METHODS: Twenty-nine patients with stage IV CRC received a combination of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (OCFL) for 3-4 months. Histological response to chemotherapy was assessed by using a tumor regression grading (TRG) score based on presence of residual tumor cells and extent of fibrosis.
RESULTS: Median age of patients was 56 (range, 37-69) years. Primary tumor location was right colon (n = 5), left colon (n = 7), and rectum (n = 17 patients). TRG scores correlated across disease sites (Spearman correlation coefficients for TRG in the primary tumor and lymph nodes was 0.59 [P = 0.005]; for the primary tumor and metastases 0.44 [P = 0.021]; and for lymph nodes and metastases 0.58 [P = 0.006]). Complete absence or poor tumor response (TRG4/5) was significantly more frequent in primary tumors (35.7%) and locoregional lymph nodes (38%) than in liver metastases (6.9%; McNemar test, P = 0.02). Two patients had a complete pathologic response (pT0N0M0).
CONCLUSIONS: In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405223     DOI: 10.1245/s10434-010-1056-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4).

Authors:  Sebastiano Biondo; Ricardo Frago; Esther Kreisler; Eloy Espin-Basany
Journal:  Int J Colorectal Dis       Date:  2017-05-11       Impact factor: 2.571

2.  Management of asymptomatic primary tumours in stage IV colorectal cancer: Review of outcomes.

Authors:  Kate Jessica Wilkinson; Wei Chua; Weng Ng; Aflah Roohullah
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

3.  Pathologic response of primary rectal cancer to oxaliplatin-based chemotherapy.

Authors:  Javier Suárez; Irene Amat; Ruth Vera; Enrique Balén; Marisa Gómez; Jose Miguel Lera
Journal:  Clin Colon Rectal Surg       Date:  2011-06

4.  Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.

Authors:  Laurence E McCahill; Greg Yothers; Saima Sharif; Nicholas J Petrelli; Lily Lau Lai; Naftali Bechar; Jeffrey K Giguere; Shaker R Dakhil; Louis Fehrenbacher; Samia H Lopa; Lawrence D Wagman; Michael J O'Connell; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

5.  Resection of Asymptomatic Primary Tumor with Synchronous Unresectable Colorectal Metastasis-Is It Reasonable?

Authors:  Mufaddal Kazi; Sanket Bankar; Avanish Saklani
Journal:  Indian J Surg Oncol       Date:  2021-10-16

6.  Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.

Authors:  J Carrasco; M Gizzi; G Pairet; V Lannoy; P Lefesvre; J-F Gigot; C Hubert; A Jouret-Mourin; Y Humblet; J-L Canon; C Sempoux; X Chapaux; E Danse; N Tinton; B Navez; M Van den Eynde
Journal:  Br J Cancer       Date:  2015-10-13       Impact factor: 7.640

7.  Lymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis.

Authors:  Jannemarie A M de Ridder; Nikki Knijn; Bastiaan Wiering; Johannes H W de Wilt; Iris D Nagtegaal
Journal:  Ann Surg Oncol       Date:  2015-05-19       Impact factor: 5.344

8.  Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.

Authors:  Surennaidoo P Naiken; Christian Toso; Laura Rubbia-Brandt; Theodoros Thomopoulos; Arnaud Roth; Gilles Mentha; Philippe Morel; Pascal Gervaz
Journal:  BMC Surg       Date:  2014-01-17       Impact factor: 2.102

9.  BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES.

Authors:  Orlando Jorge Martins Torres; Márcio Carmona Marques; Fabio Nasser Santos; Igor Correia de Farias; Anelisa Kruschewsky Coutinho; Cássio Virgílio Cavalcante de Oliveira; Antonio Nocchi Kalil; Celso Abdon Lopes de Mello; Jaime Arthur Pirola Kruger; Gustavo Dos Santos Fernandes; Claudemiro Quireze; André M Murad; Milton José de Barros E Silva; Charles Edouard Zurstrassen; Helano Carioca Freitas; Marcelo Rocha Cruz; Rui Weschenfelder; Marcelo Moura Linhares; Leonaldson Dos Santos Castro; Charles Vollmer; Elijah Dixon; Héber Salvador de Castro Ribeiro; Felipe José Fernandez Coimbra
Journal:  Arq Bras Cir Dig       Date:  2016 Jul-Sep

10.  Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy.

Authors:  Mylène Sebagh; Marc-Antoine Allard; Nelly Bosselut; Myriam Dao; Eric Vibert; Maïté Lewin; Antoinette Lemoine; Daniel Cherqui; René Adam; Antonio Sa Cunha
Journal:  Oncotarget       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.